208 related articles for article (PubMed ID: 22394107)
21. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
22. Autophagy is associated with chemoresistance in neuroblastoma.
Belounis A; Nyalendo C; Le Gall R; Imbriglio TV; Mahma M; Teira P; Beaunoyer M; Cournoyer S; Haddad E; Vassal G; Sartelet H
BMC Cancer; 2016 Nov; 16(1):891. PubMed ID: 27846885
[TBL] [Abstract][Full Text] [Related]
23. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
24. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
25. Role of chemotherapy resistance genes in outcome of neuroblastoma.
de Cremoux P; Jourdan-Da-Silva N; Couturier J; Tran-Perennou C; Schleiermacher G; Fehlbaum P; Doz F; Mosseri V; Delattre O; Klijanienko J; Vielh P; Michon J
Pediatr Blood Cancer; 2007 Mar; 48(3):311-7. PubMed ID: 16609945
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between CD133 and chemoresistance in human gastric cancer and its associated mechanism].
Zhu Y; Jiang B; Cai C; Wang S; Wu J; Yu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Feb; 17(2):168-74. PubMed ID: 24577774
[TBL] [Abstract][Full Text] [Related]
27. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
28. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
[TBL] [Abstract][Full Text] [Related]
29. Effect of cytotoxic agents and retinoic acid on Myc-N protein expression in neuroblastoma.
Aktas S; Altun Z; Erbayraktar Z; Aygun N; Olgun N
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):86-9. PubMed ID: 19550295
[TBL] [Abstract][Full Text] [Related]
30. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
31. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth.
Chuang JH; Chou MH; Tai MH; Lin TK; Liou CW; Chen T; Hsu WM; Wang PW
Int J Biochem Cell Biol; 2013 May; 45(5):944-51. PubMed ID: 23395630
[TBL] [Abstract][Full Text] [Related]
32. The MYCN enigma: significance of MYCN expression in neuroblastoma.
Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
[TBL] [Abstract][Full Text] [Related]
33. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
[TBL] [Abstract][Full Text] [Related]
34. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
Morishita N; Tsukahara H; Chayama K; Ishida T; Washio K; Miyamura T; Yamashita N; Oda M; Morishima T
Pediatr Blood Cancer; 2012 Jul; 59(1):83-9. PubMed ID: 22183914
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
36. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of infants with localized neuroblastoma based on their MYCN status.
Iehara T; Hamazaki M; Tajiri T; Kawano Y; Kaneko M; Ikeda H; Hosoi H; Sugimoto T; Sawada T;
Int J Clin Oncol; 2013 Jun; 18(3):389-95. PubMed ID: 22383024
[TBL] [Abstract][Full Text] [Related]
38. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of DNA-PKcs suppresses P-gp expression via inhibition of the Akt/NF-κB pathway in CD133-positive osteosarcoma MG-63 cells.
Li K; Li X; Tian J; Wang H; Pan J; Li J
Oncol Rep; 2016 Oct; 36(4):1973-80. PubMed ID: 27499034
[TBL] [Abstract][Full Text] [Related]
40. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death.
Li Z; Jaboin J; Dennis PA; Thiele CJ
Cancer Res; 2005 Mar; 65(6):2070-5. PubMed ID: 15781614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
